<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Montalescot, Gilles</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Eplerenone Post Myocardial Infarction Plus Standard Treatment May Prevent Adverse Cardiovascular Outcomes</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">20-21</style></pages><abstract><style  face="normal" font="default" size="100%">Early administration of eplerenone added to standard treatment in postmyocardial infarction patients appears to reduce the risk of adverse cardiovascular outcomes and heart failure, according to results from the Impact of Eplerenone on Cardiovascular Outcomes in Patients Post-Myocardial Infarction trial [REMINDER; NCT01176968].</style></abstract><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>